13620-47-8

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2-chloroacetyl)-3-(4-chlorophenyl)urea is used as an intermediate in the pharmaceutical industry for the synthesis of various biologically active compounds. Its unique chemical structure and functional groups make it a valuable building block in the development of new drugs.
Used in Agrochemicals:
In the agrochemical industry, 1-(2-chloroacetyl)-3-(4-chlorophenyl)urea is used as a starting material for the development of insecticides and fungicides. Its pesticidal activity makes it a promising candidate for protecting crops from harmful insects and fungi.
Used in Cancer Treatment Research:
1-(2-chloroacetyl)-3-(4-chlorophenyl)urea is being investigated for its potential use in the treatment of cancer. Its specific mode of action and interaction with biological targets are areas of ongoing research, with the aim of developing novel therapeutic strategies against various types of cancer.
Used in Diabetes Treatment Research:
Additionally, 1-(2-chloroacetyl)-3-(4-chlorophenyl)urea has been explored for its potential application in the treatment of diabetes. The investigation into its effects on glucose metabolism and insulin regulation could lead to the development of new treatments for managing this chronic disease.

Upstream product

• 104-12-1 p-chlorphenylisocyanate 
• 79-07-2 Chloroacetamide 
• 79-37-8 oxalyl dichloride 
• 106-47-8 4-chloro-aniline 
• 79-04-9 chloroacetyl chloride 
• 140-38-5 N-(4-chlorophenyl)urea 
• 4461-30-7 2-chloroacetylisocyanate 

Downstream Products

• 13562-14-6 N--N'-<4-chlor-phenyl>-harnstoff 
• 72546-79-3 morpholine-4-carbodithioic acid 4-(4-chloro-phenyl)-allophanoylmethyl ester 
• 76979-56-1 1-(4-Chloro-phenyl)-3-{2-[(4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-urea 
• 84325-85-9 1-(4-Chloro-phenyl)-3-{2-[4-(4-oxo-2-phenyl-4H-quinazolin-3-yl)-phenoxy]-acetyl}-urea 
• 76979-57-2 1-(4-Chloro-phenyl)-3-{2-[(6-nitro-4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-urea 
• 83315-87-1 1-(4-Chloro-phenyl)-3-{2-[6,8-dibromo-3-(3-methoxy-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-ylsulfanyl]-acetyl}-urea 
• 97399-39-8 1-(4-Chloro-phenyl)-3-{2-[5-(3,5-dibromo-2-hydroxy-phenyl)-4-p-tolyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetyl}-urea 
• 97399-33-2 1-(4-Chloro-phenyl)-3-{2-[5-(3,5-dibromo-2-hydroxy-phenyl)-4-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetyl}-urea 

Relevant academic research and scientific papers

Design, Synthesis, and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives Containing Urea Moiety

Abstract: In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives containing urea moiety were designed and synthesized, and the antitumor activity of four human tumor cells was evaluated by MTT analysis. The results showed that most of the target compounds exhibited moderate antitumor activity. In particular, the IC50 (concentration required to achieve 50% inhibition of the tumor cell proliferation) value of compound 2-((4-(4-ethylphenoxy)-6-(trifluoromethyl)pyrimidin-2-yl)thio)-N-((4-ethylphenyl)carba-moyl)acetamide for MGC-803 (human gastric carcinoma cell line) was 2.51 ± 0.17 μmol L–1, the anti-proliferative activity was significantly better than the positive control drug 5-fluorouracil. Molecular docking revealed that this compound can bind well to the active site of epidermal growth factor receptor (EGFR), and it may become a potential antitumor drug.

Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40–Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4.